ong-term clinical outcome of chronic hepatitis B naive patients treated with entecavir and tenofovir in Korea
Not Applicable
Completed
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0008111
- Lead Sponsor
- Hallym University Medical Center-Dongtan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Patients who were prescribed entecavir as an initial treatment for chronic hepatitis B between January 2011 and January 2014
Patients who were prescribed tenofovir as an initial treatment for chronic hepatitis B between December 2012 and December 2015
Exclusion Criteria
Patients who could not be followed up within 1 year after administration of entecavir or tenofovir
Patients diagnosed with liver cancer before and within 1 year after administration of entecavir or tenofovir
Patients diagnosed with other types of malignancies during the 5 years prior to administration of entecavir or tenofovir
Patients co-infected with HCV or HIV
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HCC development
- Secondary Outcome Measures
Name Time Method mortality, liver-related mortality, and other carcinoma incidence